Product Description
Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for IBD.
Mechanisms of Action: ADORA3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Palobiofarma SL
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2017-003228-54 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2019-04-09 |